All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Can KRd + HSCT overcome the poor prognosis of harboring a high-risk cytogenetic aberration?
Bookmark this article
Video series
Latest news on high-risk NDMM
During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Roberto Mina, University of Turin, Turin, IT. We asked, Can carfilzomib, lenalidomide, and dexamethasone (KRd) + hematopoietic stem cell transplantation overcome the poor prognosis of harboring a high-risk cytogenetic aberration?
In this video, Mina discusses the results of a subgroup analysis of the FORTE study (NCT02203643) evaluating the efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (KCd) or lenalidomide and dexamethasone (KRd) with or without transplant.
Video series
Latest news on high-risk NDMM
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox